Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1.
Arbutus Biopharma Corp (ABUS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Whitefort Capital David Salanic | 12,862,152 | $33,184,352 | -3% | 20.21% |
| 2. | Two Seas Capital Sina Toussi | 7,841,927 | $20,232,172 | -14% | 3.96% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,070,659 | $10,502,300 | -14% | 0.09% |
| 4. | Hudson Bay Capital Management Sander Gerber | 3,520,382 | $9,082,586 | -15% | 0.05% |
| 5. | FourWorld Capital Management John Addis | 3,000,527 | $7,741,360 | +176% | 4.93% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.95 | 1,000 | Director | 1,000 | 2015-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.31 | 4,358 | Officer | 125,542 | 2024-02-02 | Filing | |
| $2.31 | 9,593 | Officer | 181,907 | 2024-02-02 | Filing | |
| $2.31 | 9,982 | Officer | 1,485,121 | 2024-02-02 | Filing | |
| $2.31 | 10,164 | Officer, Director | 1,504,793 | 2024-02-02 | Filing | |
| $5.09 | 200,000 | Officer | 1,303,403 | 2021-12-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,390,300 | $25,975,752 | 0% | |
| 2. | 6,984,112 | $17,460,282 | 0% | |
| 3. | 5,988,883 | $14,972,208 | 0% | |
| 4. | 2,817,695 | $7,044,982 | 0% | |
| 5. | 2,396,760 | $5,991,900 | 0% |
News See All
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript
Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call.
12 Best Micro Cap Stocks To Invest In
In this piece, we will take a look at the 12 best micro cap stocks to invest in.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Q2 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2023 First Quarter Financial Results and Corporate Update Conference Call.
5 Best Debt Free Penny Stocks to Invest In
In this article, we will be taking a look at the 5 best debt free penny stocks to invest in.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Corporation Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call.
5 Penny Stocks With Biggest Upside
Denison Mines Corp. (NYSE:DNN) engages in the acquisition, exploration, development, extraction, processing, selling off, and investing of uranium properties in Canada.
5 Best High Volume Penny Stocks to Buy Now
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a biopharmaceutical company that develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United...
Billionaire Hedge Funds
